Researchers Discover Key to Drug Resistance in Common Breast Cancer Treatment

Scientists from the Florida campus of The Scripps Research Institute, the University of California, San Diego, and the University of Illinois have found that two immune system molecules (interleukin 1 beta and tumor necrosis factor alpha) may be key to the development of drug resistance in estrogen-driven breast cancers. The researchers believe this finding may open the door to novel therapeutic approaches and influence treatment decisions.


By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.